Global AI-based Clinical Trials Solution Provider Market Size, Share, Growth Analysis Report - Forecast 2034

The global AI-based Clinical Trials Solution Provider Market Size was worth around USD 302.15 Million in 2024 and is predicted to grow to around USD 1515.66 Million by 2034 with a compound annual growth rate (CAGR) of roughly 17.5% between 2025 and 2034. The report analyzes the global AI-based clinical trials solution provider market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the AI-based clinical trials solution provider industry.

Request Free Sample

AI-based Clinical Trials Solution Provider Market: Synopsis

Healthcare industry is one of the major domains which finds plethora of AI applications. Moreover, use of AI in healthcare industry is supported by big data of electronic health records and improved computational ability of AI applications. Nevertheless, AI-based Clinical Trials Solution provider, which is one of the key AI applications, also aids in effective clinical decision making process and enhances new drug molecule discoveries for treating chronic and infectious ailments such as COVID-19, Avian Flu, and Swine Flu. Clinical development is likely to witness a paradigm shift with converging of large online data sources and computing power that helps in determining clinically similar & meaningful trends in data with help of AI algorithms.

Reportedly, AI tools such as AI-based Clinical Trials Solution helps in detecting, diagnosing, treating, and predicting outcomes of chronic ailments including cardiac problems, cancer, neurological ailments, and pathological disorders.  According to NCBI, in the timespan between 2000 to 2015, it was found that success proportion of clinical trials conducted on candidates was very low. For instance, only 14% of subjects were successful in all three phases of clinical trials.

However, with use of AI in clinical trials, there was a steep reduction in cycle time of trials and improvement in clinical trial outcomes. Such moves are set to accurately and seamlessly address issues related to clinical investigations along with augmenting popularity of AI-based clinical trials solutions. This will boost AI-based Clinical Trials Solution provider market trends.

Key Insights

• As per the analysis shared by our research analyst, the global AI-based clinical trials solution provider market is estimated to grow annually at a CAGR of around 17.5% over the forecast period (2025-2034).
• Regarding revenue, the global AI-based clinical trials solution provider market size was valued at around USD 302.15 Million in 2024 and is projected to reach USD 1515.66 Million by 2034.
• The AI-based clinical trials solution provider market is projected to grow at a significant rate due to increasing complexity and costs of traditional clinical trials, the urgent need for faster drug development and time-to-market, growing demand for personalized medicine.
• Based on Applications, the Oncology segment is expected to lead the global market.
• On the basis of Phase, the Phase-I segment is growing at a high rate and will continue to dominate the global market.
• Based on the End-use, the Pharmaceutical Companies segment is projected to swipe the largest market share.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Request Free Sample

AI-based Clinical Trials Solution Provider Market: Growth Dynamics

Growth of AI-based Clinical Trials Solution provider market is subject to massive use of AI & deep learning algorithms in clinical trials for constant streaming of clinical test data for purpose of coding and storing. Apparently, use of AI-driven programs in clinical trials facilitates reduction of human intervention in data collection, thereby resulting in minimal error probability and seamless integration of clinical data with other databases.

This will amplify scope of AI-based Clinical Trials Solution provider industry. Furthermore, use of AI-driven health systems & patient support tools are set to aid clinical trials, thereby engaging and retaining subjects throughout all phases of clinical trials.

Moreover, AI-driven clinical trial solution providers assist in virtual monitoring of candidate condition and thus mitigate in-person visit to clinical trial site. Apart from this, use of AI technologies by healthcare & biotech firms helps the latter in sending of reminders & informing clinical trial progress to candidates. In addition to this, AI-based Clinical Trials Solution provider makes use of AI-driven search tools for detecting type of clinical trials through querying of clinical data of candidates.

AI-based Clinical Trials Solution Provider Market: Segmentation Analysis

The global AI-based clinical trials solution provider market is segmented based on Applications, Phase, End-use, and region.

Based on Applications, the global AI-based clinical trials solution provider market is divided into Oncology, CVD, Neurological Diseases or conditions, Metabolic diseases, Infectious diseases, Others.

On the basis of Phase, the global AI-based clinical trials solution provider market is bifurcated into Phase-I, Phase-II, Phase-III.

By End-use, the global AI-based clinical trials solution provider market is split into Pharmaceutical Companies, Academia, Others.

AI-based Clinical Trials Solution Provider Market: Report Scope    

For the record, firms such as AiCure and  Brite Health are making use of AI-based systems for monitoring patient health as well as their responses to medical treatment during clinical tests. Furthermore, these firms ensure efficiency of medical treatment and adherence to clinical trial procedures along with patient retention for completion of clinical trials. All these strategic moves will proliferate growth in size of AI-based Clinical Trials Solution provider market over forthcoming years.

Regional Landscape

North America To Lead Overall Market Growth By 2034

Growth of AI-based Clinical Trials Solution market in North America over assessment period can be attributed to various factors. Some of them include increase in acceptance of AI-driven systems in healthcare industry, rise in precision medicine practices & applications, and coining of strategy focusing on co-developing precision diagnostics and therapeutic agents as companion diagnostics for facilitating launch of effective drugs to successfully treat patients suffering from chronic ailments.

In addition to this, startup firms such as Unlearn.ai based in San Francisco are highlighting on minimizing number of subjects for clinical trials through use of AI-based tools. Apparently, third party service providers including antidote.me, Deep 6 AI, and Trials. Ai based in the U.S. have created AI apps that helps in  identifying & recruiting suitable patients for enrollment in clinical trials through exact examination of healthcare records of patients.

AI-based Clinical Trials Solution Provider Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the AI-based clinical trials solution provider market on a global and regional basis.

The global AI-based clinical trials solution provider market is dominated by players like:

• Unlearn.ai Inc.
• Saama
• Antidote Technologies Inc.
• Phesi
• Deep6.ai
• Innoplexus
• Mendel Health Inc.
• Intelligencia AI
• Median Technologies
• SymphonyAI
• BioAge Labs Inc.
• AiCure
• Consilx
• DeepLens.AI
• HaloHealth
• PHARMASEAL
• Ardigen
• Trials.ai
• Koneksa Health
• Euretos
• BioSymetrics Inc.
• Verily (Google LLC)
• Aitia
• IBM
• Exscientia

The global AI-based clinical trials solution provider market is segmented as follows;

By Applications

• Oncology
• CVD
• Neurological Diseases or conditions
• Metabolic diseases
• Infectious diseases
• Others

By Phase

• Phase-I
• Phase-II
• Phase-III

By End-use

• Pharmaceutical Companies
• Academia
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America